PTK6 (Protein Tyrosine Kinase 6)

The amplification of PTK6 may serve as an early biomarker detectable at the HGA stage, while DEK amplification appears crucial for metastatic progression and may represent a therapeutic target. Further validation is needed.

Furthermore, Bortezomib suppressed CHI3L1 secretion in vitro and in vivo, inhibiting HCC lung metastasis. This study establishes CHI3L1 as a specific biomarker and a therapeutic target for HCC pulmonary metastasis.

In summary, we identified a shared genetic architecture comprising pleiotropic cerebellar hub genes linking PSU-cancer trait pairs and described potential interventional drugs.

Applied to HER2+ breast cancer, we identify CCND1 and PTK6 signaling in tumor regions linked to trastuzumab resistance, consistent with prior studies. Our approach offers interpretable insights for multi-level resistance mechanisms, tissue-specific drug targeting, and precision medicine.

Furthermore, PTK6 was identified as a driver of PAAD proliferation, migration, and invasion. Collectively, our study elucidates TME-driven mechanisms of PAAD metastasis, identifies prognostic and therapeutic targets, and provides a framework for precision intervention.

This integrated approach, combining the in vitro validation and computational modeling, places Kim-161 and Kim-111 as promising lead compounds for targeted urothelial carcinoma therapy. The findings underscore the therapeutic potential of dual kinase/tubulin inhibition in combating aggressive malignancies, offering a robust foundation for further preclinical development.

Methyl-angolensate, byssochlamic-acid, homoharringtonine, piperacillin and cephaeline were potentially targeted therapeutic compounds for hub genes based on molecular docking. Our study firstly provides new insight into the genetic crosstalk between metastatic melanoma and vitiligo that may facilitate the development of personalized treatments.

PTK6 emerges as a critical immune infiltration-related prognostic biomarker through single-cell transcriptomic analysis.

The experimental results demonstrate that PTK6 is a novel prognostic biomarker and potential therapeutic target for CM, highlighting its strong potential for real-world clinical applications.This study provides a theoretical basis for understanding PTK6's role in CM and its application in personalized treatment. However, further large-scale, multi-center studies are needed to verify its mechanistic role and clinical value.

The RS-TME classifier is the first model integrating anoikis resistance and immune microenvironment to predict survival and immunotherapy response. Simultaneously, PTK6 targeting suppresses CM progression via Hippo-mediated anoikis resistance, providing a foundation for personalized treatment strategies.

Therefore, it is of interest to explore the anti-melanoma entities of S. nigrum. Our data show that three unique melanoma-related gene targets (CYP3A4, GBA2 and PTK6) for two unique active ingredients (diosgenin and solanocapsine) present in S. nigrum have potential role.

Our research results indicate that the autophagy-related exosome genes PTK6, ITGA3 and ITGB4 are independent risk factors for PC and may promote PC development and invasion by promoting cell-cell adhesion and cell-matrix adhesion, inhibiting tumor cell autophagy, promoting nerve infiltration, reducing CD8 + T-cell content, and increasing M0 and M2 macrophage content. Drug susceptibility analysis showed that crizotinib, tamoxifen, ixazomib, and carboplatin had inhibitory effects on ITGA3, ITGB4, and PTK6.